Please use this identifier to cite or link to this item: https://saber.ucv.ve/jspui/handle/10872/304
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarazarte, Arthur-
dc.contributor.authorLobo, Gricela-
dc.contributor.authorGamboa, Neira-
dc.contributor.authorRodrigues, Juan R.-
dc.contributor.authorCapparelli, Mario V.-
dc.contributor.authorÁlvarez-Larena, Ángel-
dc.contributor.authorLópez, Simón E.-
dc.contributor.authorCharris, Jaime E.-
dc.date.accessioned2011-06-27T18:32:00Z-
dc.date.available2011-06-27T18:32:00Z-
dc.date.issued2011-06-27-
dc.identifier.urihttp://hdl.handle.net/10872/304-
dc.description.abstractA series of phenylsubstituted pyrazolo and pyrimido benzothiazine dioxide derivatives were synthesized and investigated for their abilities to inhibit b-hematin formation, hemoglobin hydrolysis and in vivo for their antimalarial efficacy in rodent Plasmodium berghei. Compounds 3-amino-7-chloro-9-(20-methylpheyl)- 1,9-dihydro-pyrazolo-[4,3-b]benzothiazine 4,4-dioxide 2b and 2,4-diamino-8-chloro-10Hphenyl- pyrimido-[5,4-b]benzothiazine 5,5-dioxide 3a were the most promising as inhibitors of hemoglobin hydrolysis, however, their effect as inhibitors of b-hematin formation was marginal, except for compound 3-amino-7-chloro-9-(30-chlorophenyl)-1,9dihydro-pyrazolo-[4,3-b]benzothiazine 4,4-dioxide 2g. The most active compound to emerge from the in vitro and in vivo murine studies was 2b, suggesting an antimalarial activity via inhibition of hemoglobin hydrolysis, however, not as efficient as chloroquine.es_VE
dc.language.isoen_USes_VE
dc.subjectBenzothiazineses_VE
dc.subjectPyrazoles_VE
dc.subjectPyrimidinees_VE
dc.subjectPlasmodium bergheies_VE
dc.subjectb-Hematines_VE
dc.subjectHemoglobines_VE
dc.titleSynthesis and antimalarial activity of pyrazolo and pyrimido benzothiazine dioxide derivativeses_VE
dc.typeArticlees_VE
Appears in Collections:Artículos Publicados

Files in This Item:
File Description SizeFormat 
EJMChem2009.pdf303.56 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.